Although currently underutilized, granulocyte colony-stimulating factor prophylaxis as supportive cancer care provides substantial value to society. Aligning utilization with clinical guidelines would increase this value considerably.
Alison Sexton Ward, PhD
Advertisement
Articles by Alison Sexton Ward, PhD
Granulocyte-colony stimulating factors (G-CSFs) reduce the risk of febrile neutropenia in patients with cancer. This study evaluates the clinical and nonclinical value associated with G-CSFs.
Advertisement
Latest Updated Articles
- Estimating the Social Value of G-CSF Therapies in the United States
October 10th 2016
Advertisement
Advertisement
Trending on AJMC
1
FDA Panel Backs 6 Peptides for Compounding
2
Teclistamab-Talquetamab Combo Cuts Myeloma Progression Risk by 89%
3
Oncology Leaders Call for Greater Collaboration to Advance Precision Medicine, Innovative Cancer Care
4
FAQs: Cyclospora Recovery, Treatment, and Outbreak Prevention Strategies
5